NFKB1 and neoplasm: IAP antagonists modulate NF-κB activity which can enhance tumor cell killing and the immune status of a tumor by several mechanisms including the conversion of pro-tumoral M2 macrophages to pro-inflammatory M1-like macrophages, signals promoting B-cell survival and the activation of dendritic cells as well as delivering stimulatory signals to T-cells [118].